Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC
Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.
Jeremie Calais, MD, assistant clinical professor, Department of Nuclear Medicine, Ahmanson Translational Imaging Division, discusses the results from a preliminary analysis ofa phase II trial investigating 177 lutetium prostate-specific membrane antigen-617(177LuPSMA-617) in patients with metastatic castration-resistant prostate cancer.
Prostate-specific antigen (PSA) levels, which was the primary endpoint of the study, declined by at least 50% after 2 cycles of therapy. This seems early, Calais says, but the retrospective analysis data appeared promising.
